Kopion Asset Management LLC Invests $4.46 Million in Certara, Inc. (NASDAQ:CERT)

Kopion Asset Management LLC acquired a new stake in Certara, Inc. (NASDAQ:CERT) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 380,638 shares of the company’s stock, valued at approximately $4,457,000. Certara accounts for about 3.2% of Kopion Asset Management LLC’s investment portfolio, making the stock its 15th largest holding.

A number of other institutional investors also recently added to or reduced their stakes in the business. Blue Trust Inc. purchased a new position in shares of Certara during the 2nd quarter worth approximately $26,000. Innealta Capital LLC acquired a new position in Certara during the second quarter worth $36,000. Intech Investment Management LLC purchased a new position in Certara in the second quarter worth $152,000. Algert Global LLC acquired a new stake in Certara in the second quarter valued at $156,000. Finally, MQS Management LLC purchased a new stake in shares of Certara during the 2nd quarter worth $162,000. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Insider Activity at Certara

In related news, insider Leif E. Pedersen sold 51,224 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the completion of the transaction, the insider now owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the sale, the insider now directly owns 99,704 shares in the company, valued at $1,125,658.16. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the transaction, the insider now directly owns 50,091 shares of the company’s stock, valued at approximately $552,503.73. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.39% of the company’s stock.

Certara Stock Down 0.3 %

CERT stock opened at $11.21 on Wednesday. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.61 and a quick ratio of 2.61. The company’s 50 day simple moving average is $11.71 and its 200-day simple moving average is $14.50. Certara, Inc. has a 12 month low of $10.35 and a 12 month high of $19.87. The firm has a market capitalization of $1.80 billion, a PE ratio of -28.74, a P/E/G ratio of 5.40 and a beta of 1.49.

Certara (NASDAQ:CERT) last posted its earnings results on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). The company had revenue of $93.31 million during the quarter, compared to analysts’ expectations of $96.01 million. Certara had a negative net margin of 21.64% and a positive return on equity of 3.03%. Certara’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.10 EPS. Equities analysts expect that Certara, Inc. will post 0.27 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on CERT shares. Barclays lowered their price target on shares of Certara from $16.00 to $14.00 and set an “equal weight” rating on the stock in a research note on Tuesday. JMP Securities reaffirmed a “market perform” rating on shares of Certara in a report on Wednesday, July 10th. Robert W. Baird decreased their price target on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 7th. UBS Group upgraded Certara from a “neutral” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, September 27th. Finally, KeyCorp reduced their price objective on Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Six equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $17.08.

Certara Company Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.